4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $45,045.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $25.74, for a total transaction of $45,045.00. Following the completion of the sale, the insider now owns 1,737 shares in the company, valued at $44,710.38. The transaction was disclosed in a filing with the SEC, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.78, for a total transaction of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $35.04, for a total transaction of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.67, for a total transaction of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.50, for a total transaction of $171,710.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $25.25 on Friday. 4D Molecular Therapeutics, Inc. has a 1 year low of $9.44 and a 1 year high of $36.25. The stock has a market cap of $1.29 billion, a P/E ratio of -9.49 and a beta of 2.87. The firm has a 50-day moving average of $28.90 and a 200 day moving average of $20.28.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. The business had revenue of ($0.02) million for the quarter, compared to analysts’ expectations of $4.67 million. Research analysts expect that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Jefferies Financial Group increased their target price on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a report on Monday, April 1st. Barclays assumed coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They set an “overweight” rating on the stock. Royal Bank of Canada raised their price target on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. BMO Capital Markets cut their price target on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, April 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $44.22.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its position in 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after acquiring an additional 3,026 shares during the period. Wellington Management Group LLP raised its holdings in 4D Molecular Therapeutics by 4.5% in the fourth quarter. Wellington Management Group LLP now owns 180,475 shares of the company’s stock worth $3,656,000 after buying an additional 7,753 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock worth $16,539,000 after buying an additional 658,069 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in 4D Molecular Therapeutics by 5.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,596 shares of the company’s stock worth $458,000 after buying an additional 1,106 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in 4D Molecular Therapeutics by 24.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,574 shares of the company’s stock worth $113,000 after buying an additional 1,095 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.